Heng Zhang | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Dr. Heng Zhang | Molecular Biology | Best Researcher Award 

Lecturer | Nankai University | China

Dr. Zhang Heng is a Lecturer in Pharmacology at Nankai University, specializing in investigating the molecular mechanisms underlying malignant tumor progression and developing innovative drug therapies. He earned his B.S., M.S., and Ph.D. in Pharmaceutical Sciences from Nankai University, completing his doctoral studies with high distinction. Since joining the faculty as a lecturer, he has been actively engaged in teaching, mentoring, and advancing cutting-edge cancer research. Dr. Zhang has published multiple high-impact papers in prestigious SCI-indexed journals, including Molecular Cell, Signal Transduction and Targeted Therapy, and Advanced Materials. His scholarly contributions include original research on extrachromosomal DNA, tumor stem cell propagation, and nanomedicine-based immunotherapy. He also holds four patent applications and has received several top academic and innovation awards. Through his research and academic leadership, Dr. Zhang continues to make significant contributions toward improving the understanding of cancer biology and developing novel therapeutic strategies for clinical application.

Professional Profile

ORCID

Education

Dr. Zhang Heng pursued his higher education entirely at Nankai University, a leading institution in China recognized for excellence in pharmaceutical research. He began his academic journey with a Bachelor of Science degree in Pharmaceutical Sciences, where he built a strong foundation in pharmacology, molecular biology, and medicinal chemistry. Continuing at Nankai, he completed his Master of Science degree, focusing on the molecular biology of tumors and early drug discovery methodologies. His master’s research involved extensive laboratory experiments, including molecular cloning, protein analysis, and tumor cell line studies. Dr. Zhang then earned his Ph.D. in Pharmaceutical Sciences, conducting advanced research on the molecular mechanisms driving cancer progression and identifying new targets for therapeutic intervention. His doctoral studies resulted in multiple publications in internationally recognized journals. This academic path, marked by consistent excellence and research productivity, has equipped him with the knowledge and skills essential for his role as an independent researcher and educator.

Experience

Following the completion of his doctoral studies, Dr. Zhang Heng was appointed Lecturer at the College of Pharmacy, Nankai University. In this role, he has been responsible for delivering lectures in pharmacology, supervising undergraduate and graduate students, and leading research initiatives in molecular oncology. He has designed and managed multiple research projects, often collaborating with interdisciplinary teams, and has successfully bridged fundamental science with translational medicine. His experience encompasses conducting high-level molecular biology research, managing laboratory operations, and contributing to scientific publications as both first and corresponding author. He has filed patents for innovative drug delivery systems and tumor immunotherapies, demonstrating the applied impact of his work. Beyond laboratory research, Dr. Zhang has participated in national-level innovation competitions and academic conferences, presenting his findings to peers and experts in the field. His experience reflects a balance of teaching excellence, research innovation, and contribution to the broader scientific community.

Research Interest

Dr. Zhang Heng’s research interests lie at the intersection of cancer biology, molecular pharmacology, and drug innovation. He investigates the fundamental mechanisms that drive the malignant progression of tumors, including the role of extrachromosomal DNA, R-loop dynamics, and vasculogenic mimicry. His work also explores how specific proteins and epigenetic factors regulate tumor growth, immune evasion, and stem cell maintenance. In addition to basic research, Dr. Zhang focuses on developing new therapeutic strategies, such as tumor-targeted nanomedicines, biomimetic exosomes, and in situ tumor vaccines. He aims to integrate these novel approaches into translational medicine frameworks, ultimately leading to more effective, personalized cancer treatments. His interdisciplinary methodology combines molecular biology, pharmacology, nanotechnology, and immunotherapy, with the overarching goal of creating clinically applicable solutions for some of the most aggressive and treatment-resistant cancers. This research focus reflects both scientific curiosity and a commitment to advancing healthcare outcomes.

Award

Dr. Zhang Heng has been recognized for his outstanding research achievements, innovative contributions, and academic excellence through multiple prestigious awards. He received the Second Prize of the Tianjin Science and Technology Progress Award, which acknowledges impactful scientific advancements with practical applications. His innovative work in drug development and cancer therapy earned him the Gold Award at the China International “Internet Plus” Innovation and Entrepreneurship Competition. In recognition of his leadership, scientific merit, and contributions to society, he was awarded the Tianjin May Fourth Youth Medal. While a student, Dr. Zhang received the Zhou Enlai Scholarship, the highest honor granted by Nankai University, and was named Nankai University Student of the Year. These distinctions highlight not only his research excellence but also his dedication to innovation, community engagement, and the advancement of pharmacological sciences on both a national and international level.

Top Noted Publication

Dr. Zhang Heng has authored a series of impactful publications in high-ranking scientific journals, contributing significantly to the fields of molecular oncology and drug development. His research outputs span mechanistic cancer biology studies, novel therapeutic approaches, and the application of nanotechnology in tumor immunotherapy. These publications have been cited in multiple peer-reviewed articles, demonstrating their influence within the global scientific community. His work continues to inform and inspire ongoing research in cancer treatment innovation.

Publications list (single-line prompt):

Title: Extrachromosomal DNA biogenesis is dependent on DNA looping and religation by YY1–Lig3–PARylation complex
Journal: Molecular Cell
Year: 2025

Title: MTA2 triggered R-loop trans-regulates BDH1-mediated β-hydroxybutyrylation and potentiates propagation of hepatocellular carcinoma stem cells
Journal: Signal Transduction and Targeted Therapy
Year: 2021

Title: Biomimetic Immunosuppressive Exosomes that Inhibit Cytokine Storms Contribute to the Alleviation of Sepsis
Journal: Advanced Materials
Year: 2022

Title: Magnetic sculpture-like tumor cell vaccines enable targeted in situ immune activation and potent antitumor effects
Journal: Theranostics
Year: 2025

Title: Vitamin D binding protein (VDBP) hijacks Twist1 to inhibit vasculogenic mimicry in hepatocellular carcinoma
Journal: Theranostics
Year: 2024

Conclusion

Dr. Zhang Heng is a highly suitable candidate for the Research for Best Researcher Award. His combination of scientific excellence, innovation, and societal impact aligns well with the award’s criteria. With continued growth in global collaboration and academic leadership, he has the potential to become a leading figure in pharmacology and cancer research worldwide.

 

Abdullah Karaer | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Prof. Dr. Abdullah Karaer | Molecular Biology | Best Researcher Award 

Researcher, at Inonu University School of Medicine, Turkey.

Prof. Dr. Abdullah Karaer is a distinguished Turkish physician-scientist specializing in reproductive endocrinology and infertility. Born in 1977, he currently serves as Professor of Obstetrics & Gynecology at Inonu University, where he is also the Head of the IVF Unit and the Department of Obstetrics & Gynaecology. He founded and leads the Reproductive Sciences and Bioinformatics Research and Application Center at the same institution. With over two decades of experience, Dr. Karaer has contributed significantly to women’s health, fertility, and biomedical research. He integrates clinical expertise with advanced bioinformatics and omics technologies to tackle complex reproductive challenges. An active educator and mentor, he continues to shape the next generation of clinicians and scientists. His work has earned over 1000 citations, and his leadership in numerous interdisciplinary projects cements his role as a leading figure in reproductive medicine and academic innovation. 🌐🧪

Professional Profile

Scopus

ORCID

Google Scholar

🎓 Education 

Prof. Dr. Abdullah Karaer’s educational journey is a testament to his commitment to lifelong learning and interdisciplinary excellence. He earned his M.D. from Ankara University in 2001 and completed his specialization in Obstetrics & Gynaecology in 2007, defending a thesis on Y chromosome microdeletions in recurrent pregnancy loss. In 2022, he embarked on a PhD program in Stem Cells and Regenerative Medicine at Ankara University’s Stem Cell Institute, reflecting his interest in cutting-edge medical biotechnology. In 2024, he pursued an Associate’s degree in Computer Programming at Ankara University, signaling his commitment to bioinformatics and digital health. His solid grounding in clinical medicine, coupled with continuous academic development in genomics and informatics, uniquely positions him to lead translational research in reproductive sciences. 🧠📚💻

💼 Experience 

Dr. Karaer’s career spans clinical excellence, academic leadership, and pioneering research. Since 2018, he has served as Professor of Obstetrics & Gynecology at Inonu University, where he also leads the IVF Unit and the Division of Reproductive Endocrinology & Infertility. He founded the Reproductive Sciences and Bioinformatics Research and Application Center in 2019. Previously, he held roles as Associate Professor (2013–2018) and Assistant Professor (2010–2013) at the same university. His early clinical career includes posts at Merzifon Air Military Hospital and Siirt Women’s Health & Children Hospital. A dedicated educator, he mentors students at undergraduate and graduate levels, contributes to national medical education boards, and leads thesis supervision for future medical experts. His integration of patient care with translational research and data-driven solutions has set benchmarks in Turkey’s reproductive medicine landscape. 🏥📈👨‍🏫

🔬 Research Interest 

Prof. Karaer’s research is deeply rooted in reproductive sciences, with a focus on infertility, polycystic ovary syndrome (PCOS), endometriosis, oocyte quality, and assisted reproductive technologies. He harnesses multi-omics techniques—including metabolomics, transcriptomics, and metagenomics—to decode complex biological systems affecting fertility. His work examines the molecular underpinnings of follicular fluid composition, cumulus cell gene expression, and the impact of the vaginal microbiome on IVF outcomes. His interdisciplinary projects incorporate bioinformatics, proteomics, and advanced imaging, making his lab a hub for integrative reproductive biology. As a principal investigator in nationally and internationally funded studies, he collaborates on projects related to PCOS-related endometrial cancer, idiopathic male infertility, and placental pathophysiology in preeclampsia. Dr. Karaer’s innovative approach bridges bench-to-bedside research, aiming to enhance patient outcomes through precision reproductive medicine. 🧫🧬🧠

🏆 Awards 

Prof. Karaer’s career reflects a dedication to scientific excellence and public health impact. While formal award listings are not provided in this record, his leadership roles, continuous academic promotions, and invitations to lead national research projects attest to his recognition as an influential expert in reproductive medicine. He has served on national boards such as the National Medicine Specialty Board in Obstetrics & Gynecology and has been a key member of societies like the European Society of Human Reproduction and Embryology. His ongoing projects funded by TÜBİTAK, TÜSEB, and COST-EU illustrate the high level of trust and investment from both national and international scientific bodies. These honors underscore his capability to lead large-scale, multi-omics, and translational medical research projects addressing fertility and reproductive health. 🏅🌍📖

📚 Top Noted Publications

Dr. Karaer is the author of 65 scientific publications, cited over 1,095 times (Scopus) and 1,922 times (Google Scholar), with an h-index of 19 and 24 respectively. His studies appear in top-tier journals like BJOG, Andrology, Journal of Assisted Reproduction and Genetics, and Fertility and Sterility. His work spans vaginal microbiota, seminal and follicular fluid metabolomics, gene expression in cumulus cells, and endometriosis-related fertility outcomes. Notable publications include:

1. The Vaginal Microbiota Composition of Women Undergoing Assisted Reproduction

  • Journal: BJOG: An International Journal of Obstetrics & Gynaecology

  • Publication Year: 2021

  • Study Type: Prospective cohort study

  • Objective: To investigate the vaginal microbiota composition in women undergoing assisted reproduction and its potential impact on reproductive outcomes.

  • Key Findings: The study identified specific vaginal microbiota profiles associated with reproductive success, suggesting that certain microbial compositions may influence the outcomes of assisted reproductive technologies.

  • Link: PubMed Abstract

2. Metabolomics Analysis of Seminal Plasma in Patients with Idiopathic Oligoasthenoteratozoospermia Using High-Resolution NMR Spectroscopy

  • Journal: Andrology

  • Publication Year: 2020

  • Authors: A. Mumcu, A. Karaer, B. Dogan, G. Tuncay

  • Objective: To determine whether metabolites could serve as potential biomarkers for diagnosing male factor infertility by comparing seminal plasma samples from infertile men with oligoasthenoteratozoospermia (OAT) to those from normozoospermic controls.

  • Key Findings: The study found significant differences in metabolite levels between the two groups, with decreased levels of lactate, citrate, lysine, arginine, valine, glutamine, creatinine, α-ketoglutaric acid, spermine, and putrescine in OAT patients. Tyrosine levels were increased. The PLS-DA model achieved 89.29% sensitivity and 93.55% specificity in distinguishing between the groups.

  • Link: Wiley Online LibraryWiley Online Library

3. The Effect of Seminal Plasma Cadmium and Lead Levels on Semen Parameters in Male Subjects of Infertile Couples: A Prospective Cohort Study

  • Journal: Journal of Obstetrics and Gynaecology

  • Publication Year: 2020

  • Authors: Gorkem Tuncay, Abdullah Karaer, Emrullah Tanrikut, Onur Ozgul

  • Objective: To investigate the relationship between seminal plasma cadmium (Cd) and lead (Pb) levels and semen parameters in male partners of infertile couples.

  • Key Findings: Cadmium levels were significantly higher in men with hypospermia compared to those with normal semen volume (p = .049). No significant differences were observed in lead levels or other semen parameters. The findings suggest that environmental cadmium exposure may contribute to low semen volume.

  • Link: Taylor & Francis OnlineTaylor & Francis Online+1PubMed+1

4. Follicular Fluid Metabolomics in Maternal Aging

  • Journal: Journal of Assisted Reproduction and Genetics (JARG)

  • Publication Year: 2020

  • Objective: To analyze the metabolomic profile of follicular fluid in relation to maternal aging and its impact on oocyte quality and fertility.

  • Key Findings: The study identified age-related changes in the follicular fluid metabolome, suggesting that alterations in specific metabolites may affect oocyte competence and reproductive outcomes in older women.

  • Link: PubMed Abstract

5. Microarray Analysis in Endometriosis

  • Journal: Journal of Endometriosis and Pelvic Pain Disorders (JEPPD)

  • Publication Year: 2020

  • Objective: To utilize microarray analysis to identify gene expression patterns associated with endometriosis.

  • Key Findings: The study revealed specific gene expression profiles in endometrial tissues of patients with endometriosis, providing insights into the molecular mechanisms underlying the disease and potential targets for therapy.

  • Link: PubMed Abstract

Conclusion

Professor Abdullah Karaer is highly suitable for the Best Researcher Award. His multidisciplinary approach, consistent research productivity, leadership in reproductive and bioinformatics research, and proven mentorship make him a standout candidate. With minor enhancements in international engagement and digital presence, his profile would reach even greater global competitiveness.